


E KW-6002/CN

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2011 ACS on STN  
RN 155270-99-8 REGISTRY  
ED Entered STN: 24 May 1994  
CN 1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 1H-Purine-2,6-dione, 8-[2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)-  
OTHER NAMES:  
CN Istradefylline  
CN KW 6002  
FS STEREOSEARCH  
MF C20 H24 N4 O4  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, RTECS\*, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)


Double bond geometry as shown.



SET EXPAND CONTINUOUS  
E KW 6002/CN  
L1 1 S E15  
E PAROXETINE/CN  
L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2011 ACS on STN  
RN 61869-08-7 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-  
OTHER NAMES:  
CN (-)-Paroxetine  
CN (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxy)methyl)piperidine

CN Aropax  
 CN Besitram  
 CN BRL 29060  
 CN Casbol  
 CN FG 7051  
 CN Frosinor  
 CN Motivan  
 CN Paroxetine  
 CN Paxetil  
 CN Paxil  
 CN PaxPar  
 FS STEREOSEARCH  
 DR 63952-24-9  
 MF C19 H20 F N O3  
 CI COM  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS,  
 BIOTECHNO,  
 CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, EMBASE,  
 IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PS, REAXYSFILE\*, RTECS\*,  
 TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: WHO

Absolute stereochemistry. Rotation (-).



L2 1 S E27

FILE 'CAPLUS' ENTERED AT 11:22:08 ON 07 JUL 2011

L3 5 S L1 AND L2  
 L4 1 S US 20060241102/PN  
 E 5-HT ANTAGONISTS/IT  
 L5 3811 S 5-HT ANTAGONISTS/IT  
 E 5-HT REUPTAKE INHIBITORS/IT  
 L6 4404 S 5-HT REUPTAKE INHIBITORS/IT  
 L7 7867 S L5 OR L6  
 L8 6 S L1 AND L7  
 L9 3 S L8 NOT L3  
 L10 1 S L9 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2011 ACS on STN

AB It is intended to provide medicinal compns. and the like useful in  
 treating depression which contain a compound having an antagonism to  
 adenosine A2A receptor (for example, (E)-8-(3,4-dimethoxystyryl)-1,3-  
 diethyl-7-methyl-3,7-dihydro-1H-purin-2,6- dione) (I) or a pharmacol.  
 acceptable salt thereof together with an antidepressant (for example, a  
 tricyclic antidepressant, a tetracyclic antidepressant, a selective

serotonin reuptake inhibitor, a selective noradrenaline reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin/noradrenaline reuptake inhibitor, a monoamine oxidase inhibitor or a serotonin 2 antagonist). The effect of combination of I 0.08 and venlafaxine hydrochloride 5 mg/kg on depression in mice in forced swim test was examined

ACCESSION NUMBER: 2005:99358 CAPLUS Full-text  
DOCUMENT NUMBER: 142:162694  
TITLE: Medicinal compositions containing adenosine A2A receptor antagonists and other antidepressants  
INVENTOR(S): Kase, Hiroshi; Kobayashi, Minoru; Shiozaki, Shizuo; Mori, Akihisa; Seno, Naoki  
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005009444	A1	20050203	WO 2004-JP10758	20040722
<--				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2533117	A1	20050203	CA 2004-2533117	20040722
<--				
EP 1655029	A1	20060510	EP 2004-748023	20040722
<--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 4648193	B2	20110309	JP 2005-512077	20040722
<--				
US 20060241102	A1	20061026	US 2006-565239	20060119
<--				
NO 2006000958	A	20060425	NO 2006-958	20060227
<--				
PRIORITY APPLN. INFO.:			JP 2003-201549	A 20030725
<--				
			WO 2004-JP10758	W 20040722
<--				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IPCI A61K0031-52 [ICM,7]; A61K0031-137 [ICS,7]; A61K0031-335 [ICS,7];  
A61K0031-343 [ICS,7]; A61K0031-36 [ICS,7]; A61K0031-38 [ICS,7];  
A61K0031-381 [ICS,7]; A61K0031-435 [ICS,7]; A61K0031-496 [ICS,7];  
A61K0031-5375 [ICS,7]; A61K0031-55 [ICS,7]; A61K0031-553 [ICS,7];  
A61P0025-24 [ICS,7]

IPCR A61K0031-137 [I,A]; A61K0031-335 [I,A]; A61K0031-343 [I,A]; A61K0031-36 [I,A]; A61K0031-38 [I,A]; A61K0031-381 [I,A]; A61K0031-435 [I,A]; A61K0031-496 [I,A]; A61K0031-52 [I,A]; A61K0031-5375 [I,A]; A61K0031-55 [I,A]; A61K0031-553 [I,A]; A61K0045-06 [I,A]; A61P0025-24 [I,A]

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

IT 5-HT antagonists

(5-HT<sub>2</sub>; medicinal compns. containing adenosine A<sub>2A</sub> receptor antagonists and other antidepressants)

IT 5-HT reuptake inhibitors

(medicinal compns. containing adenosine A<sub>2A</sub> receptor antagonists and other antidepressants)

IT 56296-78-7, Fluoxetine hydrochloride 99300-78-4, Venlafaxine hydrochloride 155270-99-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(medicinal compns. containing adenosine A<sub>2A</sub> receptor antagonists and other antidepressants)

L11 8 S L1 AND (?SEROTONIN? OR ?TRYPTAMINE? OR 5-HT?)

L12 3 S L11 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)

L13 0 S L12 NOT (L3 OR L8)

FILE 'REGISTRY' ENTERED AT 11:31:44 ON 07 JUL 2011

E FLUOXETINE/CN

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2011 ACS on STN

RN 54910-89-3 REGISTRY

ED Entered STN: 16 Nov 1984

CN Benzenepropanamine, N-methyl-γ-[4-(trifluoromethyl)phenoxy]- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzenepropanamine, N-methyl-γ-[4-(trifluoromethyl)phenoxy]-, (±)-

OTHER NAMES:

CN (±)-Fluoxetine

CN (±)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine

CN 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine

CN Deprex

CN dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine

CN Fluoxetin Ratiopharm

CN Fluoxetine

CN Fluoxin

CN Fluval

CN N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine

CN N-Methyl-3-[4-(trifluoromethyl)phenoxy]-3-phenylpropanamine

CN Nikomed

CN NSC 283480


CN Seronil

CN Symbiax

DR 57226-07-0, 52341-67-0

MF C17 H18 F3 N O

CI COM  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS,  
 BIOTECHNO,  
 CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN,  
 CSNB,  
 DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IMSRESEARCH,  
 IPA, MEDLINE, MRCK\*, MSDS-OHS, PS, REAXYSFILE\*, RTECS\*, SPECINFO,  
 TOXCENTER, USAN, USPAT2, USPATFULL, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: WHO



L14 1 S E63  
 L15 0 S L1 AND L14  
 L16 1 S L1

FILE 'CAPLUS' ENTERED AT 11:32:20 ON 07 JUL 2011

L17 6 S L1 AND L14  
 L18 3 S L17 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)  
 L19 1 S L18 NOT (L8 OR L3)  
 L20 1 S L19 NOT L10

L20 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2011 ACS on STN

AB Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist (e.g. a xanthine derivative) to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.

ACCESSION NUMBER: 2004:1080800 CAPLUS Full-text  
 DOCUMENT NUMBER: 142:33005  
 TITLE: A method using an adenosine A2A receptor antagonist for treating an anxiety disorder  
 INVENTOR(S): Kase, Hiroshi; Seno, Naoki; Shiozaki, Shizuo; Kobayashi, Minoru; Kase, Junya  
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 96 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004108137	A1	20041216	WO 2004-JP8486	20040610

<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

AU 2004244906	A1	20041216	AU 2004-244906	20040610
<--				
CA 2528710	A1	20041216	CA 2004-2528710	20040610
<--				
EP 1631294	A1	20060308	EP 2004-746014	20040610
<--				
EP 1631294	B1	20100915		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,			
HR				
CN 1787821	A	20060614	CN 2004-80012845	20040610
<--				
BR 2004011120	A	20060718	BR 2004-11120	20040610
<--				
JP 2006527264	T	20061130	JP 2006-516839	20040610
<--				
AT 481101	T	20101015	AT 2004-746014	20040610
<--				
ES 2349535	T3	20110104	ES 2004-746014	20040610
<--				
US 20060281770	A1	20061214	US 2005-553250	20051017
<--				
KR 2006037252	A	20060503	KR 2005-7021878	20051116
<--				
MX 2005013148	A	20060317	MX 2005-13148	20051205
<--				
ZA 2005009903	A	20100526	ZA 2005-9903	20051206
<--				
NO 2005005907	A	20051213	NO 2005-5907	20051213
<--				
IN 2006CN00077	A	20070629	IN 2006-CN77	20060106
<--				
PRIORITY APPLN. INFO.:			US 2003-509046P	P 20030610
<--				
			US 2003-532793P	P 20031224
<--				
			WO 2004-JP8486	W 20040610
<--				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 142:33005

IPCI A61K0031-522 [ICM,7]; A61K0031-519 [ICS,7]; A61P0025-22 [ICS,7]

IPCR A61K0031-00 [I,A]; A61K0031-519 [I,A]; A61K0031-522 [I,A]; A61K0045-06  
[I,A]; A61P0025-22 [I,A]

CC 1-11 (Pharmacology)

IT 69-89-6D, Xanthine, derivs. 51389-37-8 99331-25-6D,

Triazolopyrimidine, derivs. 155270-99-8 262452-04-0  
 377727-87-2  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (adenosine A2A receptor antagonist for treating anxiety disorders)  
 IT 28981-97-7, Alprazolam 36505-84-7, Buspirone 54910-89-3,  
 Fluoxetine  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (adenosine A2A receptor antagonist for treating anxiety disorders,  
 and

E KASE HIROSHI?/AU  
 L21 0 S E73-74,76  
 L22 241 S E73-E74,E76  
 E KOBAYASHI MINORU?/AU  
 L23 438 S E85-E88  
 E SHIOZAKI SHIZUO?/AU  
 L24 49 S E97-E98  
 E MORI AKIHISA?/AU  
 L25 237 S E109-E112  
 E SENO NAOKI?/AU  
 L26 53 S E121-E124  
 L27 977 S L22 OR L23 OR L24 OR L25 OR L26  
 L28 2 S L27 AND (L6 OR L7)  
 L29 11 S L27 AND (?SEROTONIN? OR ?TRYPTAMINE? OR 5-HT?)  
 L30 11 S L28 OR L29  
 L31 10 S L30 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)  
 L32 9 S L31 NOT (L3 OR L8 OR L10)

FILE 'CAPLUS' ENTERED AT 11:40:49 ON 07 JUL 2011  
 E ADENOSINE RECEPTORS/IT  
 L33 64357 S E134,E139,E141  
 L34 8374 S ADENOSINE RECEPTORS/IT  
 L35 64357 S L33 OR L34  
 L36 68 S L27 AND L35  
 L37 63 S L36 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)  
 L38 62 S L37 NOT (L3 OR L8 OR L10 OR L32)  
 L39 0 S L38 AND (?SEROTONIN? OR 5-HT? OR ?TRYPTAMIN?)